Elaine Karis

Featured in:

Articles

Improving resource utilisation in SLE drug development through innovative trial design

Jul 25, 2023 | lupus.bmj.com | Elaine Karis |Joan T Merrill |Anca D. Askanase |Sandra Garces

Adaptive design of the phase IIb trials for rozibafusp alfa and efavaleukin alfa in SLEAn adaptive design is being used in two ongoing phase IIb double-blind, placebo-controlled, dose-ranging, multicentre studies at Amgen evaluating the safety and efficacy of rozibafusp alfa (AMG 570) (NCT04058028) and efavaleukin alfa (AMG 592) (NCT04680637).

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.